MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index

BACKGROUND: Treatment resistance is a major clinical challenge of diffuse large B-cell lymphoma (DLBCL) where approximately 40% of the patients have refractory disease or relapse. Since DLBCL is characterized by great clinical and molecular heterogeneity, the purpose of the present study was to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Due, Hanne, Brøndum, Rasmus Froberg, Young, Ken H., Bøgsted, Martin, Dybkær, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082970/
https://www.ncbi.nlm.nih.gov/pubmed/32192453
http://dx.doi.org/10.1186/s12885-020-6643-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082970/
https://www.ncbi.nlm.nih.gov/pubmed/32192453
http://dx.doi.org/10.1186/s12885-020-6643-8

Ejemplares similares